{
  "run_id": "d9353ed8-2bcb-46ae-a9a1-998e84076369",
  "prompt_variant_id": "24f52b58-ad51-45c7-8e2e-fe92c968ecfd",
  "api_config_name": "model_gpt_4_turbo",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T23:31:54.161393",
  "end_time": "2025-09-01T23:31:56.064002",
  "duration_ms": 1899.5749950408936,
  "success": true,
  "error_message": "",
  "entities_extracted": 20,
  "entities_mapped": 11,
  "extraction_completeness": 1.25,
  "mapping_accuracy": 0.6666666666666666,
  "precision": 0.7142857142857143,
  "recall": 0.9375,
  "f1_score": 0.8108108108108109,
  "compliance_score": 1.0,
  "token_usage": 4752,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "Conditions",
        "position": "12",
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "Conditions",
        "position": "41",
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "34",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "measurable disease",
      "type": "condition",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "85",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "RECIST 1.1",
      "type": "procedure",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "104",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": null,
        "value": "0-1",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "124",
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.85,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "152",
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "191",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Trastuzumab Deruxtecan",
      "type": "medication",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "209",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "250",
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "272",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "breastfeeding",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "283",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": "27",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": "68",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": "82",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "medication",
      "attributes": {
        "status": "past",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": "163",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefTitle",
        "position": "22",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefTitle",
        "position": "43",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "officialTitle",
        "position": "41",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "officialTitle",
        "position": "68",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "Mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Direct match to condition with specific cancer type and biomarker status.",
      "id": "c5500818-6689-4df3-badc-468431938cff",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Direct match to condition with specific cancer type indicating metastasis.",
      "id": "19a7c8ae-5576-4aae-9c70-db76c9687a16",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Metastatic Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "Direct match to condition combining cancer type, metastasis, and biomarker status.",
      "id": "f41cc5fb-4d8c-4e78-ad72-662278f707a6",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "Mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "RECIST 1.1 assessment",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "Mapped to a cancer-related procedure for disease measurement.",
      "id": "0e5f37a4-323d-4bab-b156-4ac03d796172",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "Direct match to ECOG performance status with specified range.",
      "id": "0828e73b-cce5-483f-8163-d11646432851",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "Direct match to a specific medication used in cancer treatment.",
      "id": "df4cc49b-3c42-444e-9650-e63b70594365",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Active brain metastases",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 9",
      "mapping_rationale": "Direct match to a cancer condition indicating specific site of metastasis.",
      "id": "842aa91f-0151-4377-a4f3-8af1014464d4",
      "llm_source_text_fragment": "Entity index 9",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "HER2-targeted therapy",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "Mapped to a general category of cancer-related medication targeting HER2.",
      "id": "52a863a6-d26d-45d6-afa7-193703abbce4",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "Mapped to a genomic variant indicating HER2-positive status.",
      "id": "9bfacfa7-b593-4daa-bd54-ab32614dc6c3",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "trastuzumab-based therapy",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 15",
      "mapping_rationale": "Mapped to past medication indicating a specific type of HER2-targeted therapy.",
      "id": "7b7cec9a-4915-48c6-ac44-067af7a8d56f",
      "llm_source_text_fragment": "Entity index 15",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-Positive",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 16",
      "mapping_rationale": "Mapped to a genomic variant indicating HER2-positive status.",
      "id": "ad24fe59-b895-4c0b-8eea-585a9a8656df",
      "llm_source_text_fragment": "Entity index 16",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}